
Breaking down the side effects of GLP-1 treatments
Dear Dr. Roach: In your recent column, you addressed a situation concerning insulin resistance, including weight gain. You mention that although there are drugs that work directly with insulin resistance, drugs in the glucagon-like peptide-1 agonist class (such as liraglutide and semaglutide) reduce risk of heart disease, promote weight loss and protect against serious complications. However, after investigating these two drugs, I found many side effects and warnings. Could you please address the warnings? -- S.T.







